<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83234">
  <stage>Registered</stage>
  <submitdate>3/10/2008</submitdate>
  <approvaldate>22/02/2011</approvaldate>
  <actrnumber>ACTRN12611000205932</actrnumber>
  <trial_identification>
    <studytitle>Effect of the probiotic bacterium Escherichia coli Nissle 1917 on symptom pattern and immunologic function in patients suffering from irritable bowel syndrome with diarrhoea</studytitle>
    <scientifictitle>Effect of the probiotic bacterium Escherichia coli Nissle 1917 on symptom pattern and immunologic function in patients suffering from irritable bowel syndrome with diarrhoea</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diarrhoea-predominant Irritable Bowel Syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Inflammatory bowel disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Probiotic bacteria E.coli Nissle (Mutaflor) will be orally administered to the participant. 1 tablet, 100mg for 4 days and then 2 tablets, 200mg for the next 17 days.Treatment of probiotic bacteria tablet will commence post a permability test which includes a 24hr urine save.</interventions>
    <comparator>Not applicable</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To assess the improvement of symptoms  in partcipants suffering from  Diarrhoea predominant Irritable Bowel Syndromes (D-IBS) during treatment with the Escherichia coli Nissle 1917 (EcN) (Mutaflor) measured with previously standardised questionnaires.</outcome>
      <timepoint>Screening, Baseline and at 3 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Assess improvement of quality of life with participants suffering from Diarrhoea predominant Irritable Bowel Symptoms during treatment with the Escherichia coli Nissle 1917 (EcN) (Mutaflor) measured with previously standardised questionnaires.</outcome>
      <timepoint>Screening, Baseline and at 3 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The effect of the treatment on intestinal and colonic permeability. This will be measured via a permabiliy test which includes a 24 hour urine save</outcome>
      <timepoint>Baseline and at 3 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Peripheral Blood Mononuclear Cells (PBMC)-mediated cytokine secretion, blood serum cytokine levels, cytokine Messenger Ribonucleic acid (mRNA) production</outcome>
      <timepoint>Screening, Baseline and 3 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Questionnaires:- Stress Questionnaire , Hospital Anxiety and Depresson Score, Irritable Bowel Syndrome Quality of Life (IBSQoL), Bowel Disease Questionnaire (BDQ) Rome II and Rome III, Irritable Bowel Syndrome Symptom Score(IBSS)</outcome>
      <timepoint>Screening, Baseline and 3 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>symptoms consistent with diarrhoea predominant IBS according to the Rome III criteria;not received antibiotics 4 weeks prior ;not taking immunosuppressive medication;not taking laxatives and prokinetic drugs for 2 weeks;able to sign consent;</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Eligible Particpants will be deemed healthy unless they have the following..previous abdominal or gynaecologyical surgery (except appendectomy and cholecystectomy); previous gastrointestinal cancer;history of other diseases known to affect colonic motility; known peptic ulcer disease;</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/01/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Department of Health</primarysponsorname>
    <primarysponsoraddress>Level 13, 11 Waymouth Street
Adelaide, SA 5000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Royal Adelaide Hospital</fundingname>
      <fundingaddress>Department of Gastroenterology
NorthTce 
Adelaide SA 5000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Pharma -Zentrale GMBH</sponsorname>
      <sponsoraddress>Loerfeid Str 20
58313 Herdecke</sponsoraddress>
      <sponsorcountry>Germany</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>.                                                                                                                                                                                                               
                                                                                                                                                                                  
                                                                                                                                                                                  
                                                                                                                                                                                  
                                                                                                                                                                                  

                                                                                         
                                                                                         
                                                                                                                                                     
                                                                                                                                                                                  
                                                                                                                                                                                  
                                                                                                                                                                                  
                                                                                                                                                                                  
.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital Human Research Ethic Committee</ethicname>
      <ethicaddress>Royal Adelaide Hospital 
North Tce
Adelaide SA 5000</ethicaddress>
      <ethicapprovaldate>11/02/2008</ethicapprovaldate>
      <hrec>070226</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>A/Prof Jane Andrews</name>
      <address>Department of Gastroenterology 
Ward Q7
North Tce
Adelaide SA 5000</address>
      <phone>+61 8 8222 5207</phone>
      <fax />
      <email>jane.andrews@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>A/Prof Jane Andrews</name>
      <address>Department of Gastroenterology 
Royal Adelaide Hospital 
Ward Q7
North Tce
Adelaide SA 5000</address>
      <phone>+61 8 8222 5207</phone>
      <fax />
      <email>jane.andrews@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>